Androgens for postmenopausal women's health?

Endocrine

Volumn 42, Issue 3, 2012, Pages 514-520

  Montalcini, Tiziana ^a   Migliaccio, Valeria ^a   Ferro, Yvelise ^a   Gazzaruso, Carmine ^b,c   Pujia, Arturo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Vascular and Endocrine Metabolic Diseases Unit and the Centre for Applied Clinical Research (CeRCA) Clinical Institute Beato Matteo   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Adipose tissue; Androgens; Atherosclerosis; Menopause; Women

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; METHYLTESTOSTERONE; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCOUPLING PROTEIN 1;

ADIPOSE TISSUE; AGING; ANDROGEN THERAPY; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BODY FAT DISTRIBUTION; BREAST CANCER; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; LIBIDO DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; WOMEN'S HEALTH; AGED; CARDIOVASCULAR FUNCTION; DRUG EFFECT; FEMALE; MIDDLE AGED; PHYSIOLOGY;

ADIPOSE TISSUE; AGED; ANDROGENS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; WOMEN'S HEALTH;

EID: 84875795721     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9692-1     Document Type: Review

References (100)

1. P.A. Sarafidis, S.I. McFarlane, G.L. Bakris, Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr. Diab. Rep. 6, 219-224 (2006)
2. B. Hildrum, A. Mykletun, A.A. Dahl, K. Midthjell, Metabolic syndrome and risk of mortality in middle-aged versus elderly individuals: the Nord-Trondelag Health Study (HUNT). Diabetologia 52, 583-590 (2009)
3. M.A. Allison, J.E. Manson, R.D. Langer, J.J. Carr, J.E. Rossouw, M.B. Pettinger, L. Phillips, B.B. Cochrane, C.B. Eaton, P. Greenland, S. Hendrix, J. Hsia, J.R. Hunt, R.D. Jackson, K.C. Johnson, L.H. Kuller, J. Robinson, Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 15(4 Pt 1), 639-647 (2008)
4. J.W. Lin, J.L. Caffrey, M.H. Chang, Y.S. Lin, Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality-cohort analysis from the Third National Health and Nutrition Examination Survey. J. Clin. Endocrinol. Metab. 95, 4258-4267 (2010)
5. Data and Information on Women's Health in the European Union, Technische Universität Dresden, Germany, European Communities, ISBN-978-92-79-13659-7 (2009)
6. S. Hulley, D. Grady, T. Bush et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280, 605-613 (1998)
7. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002)
8. M. Canonico, G. Plu-Bureau, G.D. Lowe, P.Y. Scarabin, Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 31(336), 1227-1231 (2008)
9. A. Dunaif, Insulin resistance in polycystic ovarian syndrome. Ann. N. Y. Acad. Sci. 687, 60-64 (1993)
10. A. Dunaif, Hyperandrogenemia is necessary but not sufficient for polycystic ovary syndrome. Fertil. Steril. 80, 262-263 (2003)
11. C.D. Christakou, E. Diamanti-Kandarakis, Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health (LondEngl) 4, 583-594 (2008)
12. A. Frontini, S. Cinti, Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab. 11(4), 253-256 (2010)
13. L. Cao, E.Y. Choi, X. Liu, A. Martin, C. Wang, X. Xu, M.J. During, White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis cell. Metabolism 14, 324-338 (2011)
14. H.M. Feldmann, UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermo neutrality. Cell Metab. 9, 203-209 (2009)
15. S. Enerback, The origins of brown adipose tissue. N. Engl. J. Med. 360, 2021-2023 (2009)
16. N. Petrovic, T.B. Walden, I.G. Shabalina, J.A. Timmons, B. Cannon, J. Nedergaard, Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J. Biol. Chem. 285, 7153-7164 (2010)
17. J. Ishibashi, P. Seale, Beige can be slimming. Science 328, 1113-1114 (2010)
18. M. Garaulet, F. Perez-Llamas, T. Fuente, S. Zamora, F.J. Tebar, Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur. J. Endocrinol. 143, 657-666 (2000)
19. C.S. Fox, J.M. Massaro, U. Hoffmann, K.M. Pou, P. Maurovich-Horvat, C.Y. Liu, R.S. Vasan, J.M. Murabito, J.B. Meigs, L.A. Cupples, R.B. D'Agostino Sr, C.J. O'Donnell, Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 3(116), 39-48 (2007)
20. E.E. Kershaw, J.S. Flier, Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548-2556 (2004)
21. M.M. Ibrahim, Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11, 11-18 (2010)
22. H. Xu, G.T. Barnes, Q. Yang et al., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112, 1821-1830 (2003)
23. K. Aoki, A. Nakajima, K. Mukasa et al., Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J. Steroid Biochem. Mol. Biol. 85, 469-472 (2003)
24. L.D. Valle, V. Toffolo, A. Nardi et al., Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J. Endocrinol. 190, 129-139 (2006)
25. K.K. Dhatariya, K.S. Nair, Dehydroepiandrosterone: is there a role for replacement? Mayo Clin. Proc. 78, 1257-1273 (2003)
26. F. Labrie, A. Belanger, J. Simard, L. Van, C. Labrie, DHEA and peripheral androgen and estrogen formation: intracinology. Ann. N. Y. Acad. Sci. 774, 16-28 (1995)
27. J.R. Ducharme, M.G. Forest, E. DePeretti, M. Sempe, R. Collu, J. Bertrand, Plasma adrenal and gonadal sex steroids in human pubertal development. J. Clin. Endocrinol. Metab. 42, 468-476 (1976)
28. M.R. Smith, B.T. Rudd, A. Shirley, P.H. Rayner, J.W. Williams, N.M. Duignan, P.V. Bertrand, A radioimmunoassay for the estimation of serum dehydroepiandrosterone sulphate in normal and pathological sera. Clin. Chim. Acta 65, 5-13 (1975)
29. N. Orentreich, Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59, 551-555 (1984)
30. P.A. Komesaroff, Unravelling the enigma of dehydroepiandrosterone: moving forward step by step. Endocrinology 149, 886-888 (2008)
31. D. Liu, J.S. Dillon, Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 69, 279-289 (2004)
32. D. Liu, M. Iruthayanathan, L.L. Homan et al., Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology 149, 889-898 (2008)
33. B. Goodwin, M.R. Redinbo, S.A. Kliewer, Regulation of cyp3a gene transcription by the pregnane x receptor. Annu. Rev. Pharmacol. Toxicol. 42, 1-23 (2002)
34. S.A. Kliewer, B. Goodwin, T.M. Willson, The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23, 687-702 (2002)
35. L.B. Moore, D.J. Parks, S.A. Jones, R.K. Bledsoe, T.G. Consler, J.B. Stimmel, B. Goodwin, C. Liddle, Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275, 15122-15127 (2000)
36. K. Swales, M. Negishi, CAR, driving into the future. Mol. Endocrinol. 18, 1589-1598 (2004)
37. S.L. Ripp, J.L. Fitzpatrick, J.M. Peters, R.A. Prough, Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor. Drug Metab. Dispos. 30, 570-575 (2002)
38. E. Barrett-Connor, A. Ferrara, Dehydroepiandrosterone, dehydroepiandrosteronesulfate, obesity, waist-hip ratio, and non insulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 81, 59-64 (1996)
39. J.E. Nestler, C.O. Barlascini, J.N. Clore, W.G. Blackard, Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metab. 66, 57-61 (1988)
40. P. Ebeling, V.A. Koivisto, Physiological importance of dehydroepiandrosterone. Lancet 343, 1479-1481 (1994)
41. D.P. Trivedi, K.T. Khaw, Dehydroepiandrosterone sulfate and mortality in elderly men and women. J. Clin. Endocrinol. Metab. 86, 4171-4177 (2001)
42. M. Maggio, F. Lauretani, G.P. Ceda, S. Bandinelli, S. Basaria, A. Ble, J. Egan et al., Association between hormones and metabolic syndrome in older Italian men. J. Am. Geriatr. Soc. 54, 1832-1838 (2006)
43. M. Maggio, F. Lauretani, G.P. Ceda, S. Bandinelli, S. Basaria, G. Paolisso, A. Ble et al., Association of ormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study. Am. J. Physiol. Endocrinol. Metab. 292, E353-E358 (2007)
44. J.J. Hernandez-Morante, F. Milagro, J.A. Gabaldon, J.A. Martinez, S. Zamora, M. Garaulet, Effect of DHEA-sulfate on adiponectin gene expression in adipose tissue from different fat depots in morbidly obese humans. Eur. J. Endocrinol. 155, 593-600 (2006)
45. F. Machinal-Quélin, M.N. Dieudonné, R. Pecquery, M.C. Leneveu, Y. Giudicelli, Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. Endocrine 18, 179-184 (2002)
46. S.B. Pedersen, J.M. Bruun, F. Hube, K. Kristensen, H. Hauner, B. Richelsen, Demostration of estrogen receptor subtypes alpha and beta in human adipose tissue: influences of adipose cell differentiation and fat depot localization. Mol. Cell. Endocrinol. 182, 27-37 (2001)
47. D. Mino, D. Amato, M.L. Cuevas, M.E. Fonseca, G. Búrbano, N. Wacher, A. Lifshitz, Relationship of insulin resistance and overweight with cortisol and dehydroepiandrosterone-sulfate levels. Arch. Med. Res. 33, 524-530 (2002)
48. N. Tagawa, E. Minamitani, Y. Yamaguchi, Y. Kobayashi, Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11b-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue. Steroids 76, 1546-1553 (2011)
49. I.J. Bujalska, S. Kumar, P.M. Stewart, Does central obesity reflect ''Cushing's disease of the omentum''? Lancet 349, 1210-1213 (1997)
50. J.J. Hernandez-Morante, D. Cerezo, R.M. Cruz, E. Larque, S. Zamora, M. Garaulet, Dehydroepiandrosterone-sulfate modifies human fatty acid composition of different adipose tissue depots. Obes Surg 21, 102-111 (2011)
51. K. Imai, N. Kudo, M. Koyama et al., Effects of dehydroepiandrosterone on oleic acid accumulation in rat liver. Biochem. Pharmacol. 65, 1583-1591 (2003)
52. Y.R. Lea-Currie, P. Wen, M.K. McIntosh, Dehydro-epiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem. Biophys. Res. Commun. 248, 497-504 (1998)
53. G. De Pergola, M. Zamboni, M. Sciaraffia et al., Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women. Int. J. Obes. Relat. Metab. Disord. 20, 1105-1110 (1996)
54. J.J. Hernandez-Morante, F. Perez-de-Heredia, J.A. Lujan et al., Role of DH EA-S on body fat distribution: gender- and depot-specific stimulation of adipose tissue lipolysis. Steroids 73, 209-215 (2008)
55. D.J. Evans, R.G. Hoffmann, R.K. Kalkhoff, A.H. Kissebah, Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin. Endocrinol. Meta. 57, 304-310 (1983)
56. J.C. Lovejoy, G.A. Bray, M.O. Bourgeois et al., Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women - a clinical research center study. J. ClinEndocrinol. Metab. 81, 2198-2203 (1996)
57. S. Morimoto, C. Fernandez-Mejia, G. Romero-Navarro et al., Testosterone effect on insulin content, messenger ribonucleic acid levels, promoter activity, and secretion in the rat. Endocrinology 142, 1442-1447 (2001)
58. M. Perello, D. Castrogiovanni, A. Giovambattista et al., Impairment in insulin sensitivity after early androgenization in the post-pubertal female rat. Life Sci. 80, 1792-1798 (2007)
59. D. Simon, M.A. Charles, N. Lahlou et al., Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: A3-month randomized placebo-controlled trial. Diabetes Care 24, 2149-2151 (2001)
60. G. Corona, M. Monami, G. Rastrelli, A. Aversa, A. Sforza, A. Lenzi et al., Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int. J. Androl. 34, 401-528 (2011)
61. M. Grossmann, E.J. Gianatti, J.D. Zajac, Testosterone and type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17, 247-256 (2010)
62. J.Y. Oh, E. Barrett-Connor, N.M. Wedick, D.L. Wingard, Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 25, 55-60 (2002)
63. D.E. Laaksonen, L. Niskanen, K. Punnonen, K. Nyyssonen, T.P. Tuomainen, V.P. Valkonen et al., Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27, 1036-1041 (2004)
64. R.K. Stellato, H.A. Feldman, O. Hamdy, E.S. Horton, J.B. McKinlay, Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23, 490-494 (2000)
65. T. Vikan, H. Schirmer, I. Njolstad, J. Svartberg, Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur. J. Endocrinol. 162, 747-754 (2010)
66. R. Haring, H. Volzke, S.B. Felix, S. Schipf, M. Dorr, D. Rosskopf et al., Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 58, 2027-2031 (2009)
67. V. Kupelian, S.T. Page, A.B. Araujo, T.G. Travison, W.J. Bremner, J.B. McKinlay, Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J. Clin. Endocrinol. Metab. 91, 843-850 (2006)
68. E.R. Simpson, S.R. Davis, Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142, 4589-4594 (2001)
69. S.R. Davis, Cardiovascular and cancer safety of testosterone in women. Curr. Opin. Endocrinol. Diabetes Obes. 18, 198-203 (2011)
70. P.B. Grino, J.E. Griffin, J.D. Wilson, Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126, 1165-1172 (1990)
71. S.L. Davison, R. Bell, S. Donath, J.G. Montalto, S.R. Davis, Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 90, 3847-3853 (2005)
72. A. Vermeulen, Plasma androgens in women. J. Reprod. Med. 43, 725-733 (1998)
73. C.A. Quigley, A. DeBellis, K.B. Marschke, M.K. El-Awady, E.M. Wilson, French FF androgen receptor defects: historical, clinical and molecular perspectives. Endocr. Rev. 16, 271-321 (1995)
74. R.I. Maro, Williams, T. Dawood, S. Ling, A. Dai, R. Lew, K. Myles, J.W. Funders, K. Sudhir, P.A. Komesaroff, Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J. Clin. Endocrinol. Metab. 89, 4708-4715 (2004)
75. M.R. Williams, S. Ling, T. Dawood, K. Hashimura, A. Dai, H. Li, J.P. Liu, J.W. Funder, K. Sudhir, P.A. Komesaroff, Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J. Clin. Endocrinol. Metab. 87, 176-181 (2002)
76. S. Diano, T.L. Horvath, G. Mor, T. Register, M. Adams, N. Harada, Naftolin F aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6, 21-28 (1999)
77. F. Bayard, S. Clamens, F. Meggetto, N. Blaes, G. Delsol, Liu et al. Androgens and cardiovascular disease endocrine reviews, 24:313-340 Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 136, 1523-1529 (2003)
78. S.M. Kahn, D.J. Hryb, A.M. Nakhla, N.A. Romas, W. Rosner, Sex hormone-binding globulin is synthesized in target cells. J. Endocrinol. 175, 113-120 (2002)
79. W. Rosner, D.J. Hryb, M.S. Khan, A.M. Nakhla, N.A. Romas, Androgen and estrogen signaling at the cell membrane via G proteins and cyclic adenosine monophosphate. Steroids 64, 100-106 (1999)
80. K. Higashiura, R.S. Mathur, P.V. Halushka, Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. J CardiovascPharmacol 29, 311-315 (1997)
81. H. Hanke, C. Lenz, B. Hess, K.D. Spindler, W. Weidemann, Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103, 1382-1385 (2001)
82. C.A. Heinlein, C. Chang, The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. 16, 2181-2187 (2002)
83. K.M. English, R.D. Jones, T.H. Jones, A.H. Morice, K.S. Channer, Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J. Endocrinol. Invest. 25, 455-458 (2002)
84. S.H. Golden, A. Maguire, J. Ding, J.R. Crouse, J.A. Cauley, H. Zacur, M. Szklo, Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am. J. Epidemiol. 1(155), 437-445 (2002)
85. T. Montalcini, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone, A. Pujia, Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr. Metab. Cardiovasc. Dis. 17, 705-711 (2007)
86. T. Montalcini, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone, A. Pujia, Endogenous testosterone and endothelial function in postmenopausal women. Coron. Artery Dis. 18, 9-13 (2007)
87. S. Worboys, D. Kotsopoulos, H. Teede, B. McGrath, S.R. Davis, Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J. Clin. Endocrinol. Metab. 86, 158-161 (2001)
88. P. Clarkson, D.S. Celermajer, A.J. Powe, A.E. Donald, R.M. Henry, J.E. Deanfield, Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 96, 3378-3383 (1997)
89. D.S. Celermajer, M.R. Adams, P. Clarkson, J. Robinson, R. McCredie, A. Donald, J.E. Deanfield, Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 334, 150-154 (1996)
90. D.S. Celermajer, K.E. Sorensen, V.M. Gooch, D.J. Spiegelhalter, O.I. Miller, I.D. Sullivan, J.K. Lloyd, J.E. Deanfield, Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340, 1111-1115 (1992)
91. P. Yue, K. Chatterjee, C.M. Beales, P.A. Poole-Wilson, P. Collins, Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91, 1154 (1995)
92. C.M. Webb, J.G. McNeill, C.S. Hayward, D. de Zeigler, P. Collins, Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100, 1690 (1999)
93. T.M. Chou, K. Sudhir, S.J. Hutchison, E. Ko, T.M. Amindon, P. Collins, K. Chatterjee, Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 94, 2614-2619 (1996)
94. N.B. Watts, N. Morris, M.C. Timmons, W.A. Addison, B. Wiita, L.J. Downey, Comparison of oral oestrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid lipoprotein profiles in surgical menopause. Obstet. Gynecol. 85, 529-537 (1995)
95. L.R. Hickok, C. Toomey, L. Speroff, A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. ObstetGynecol 82, 919-924 (1993)
96. S.R. Davis, P.I. McCloud, B.J.G. Strauss, H.G. Burger, Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21, 227 (1995)
97. J.W.W. Studd, W.P. Colins, S. Chakravarti, Estradiol and testosterone implants in the treatment of psychosexual problems in postmenopausal women. Br. J. Obstet. Gynaecol. 84, 314 (1977)
98. H.G. Burger, J. Hailes, J. Nelson, M. Menelaus, Effect of combined implants of estradiol and testosterone on libido in postmenopausal women. Br. Med. J. 294, 936 (1987)
99. G.F. Allan, P. Tannenbaum, T. Sbriscia, O. Linton, M.T. Lai, D. Haynes-Johnson, S. Bhattacharjee, X. Zhang, Z. Sui, S.G. Lundeen, A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 32, 41-51 (2007)
100. C. Trolle, B. Hjerrild, L. Cleemann, K.H. Mortensen, C.H. Gravholt, Sex hormone replacement in Turner syndrome. Endocrine 41, 200-219 (2012)